Bio Plus Co (XKRX:099430) Debt-to-Equity : 0.04 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bio Plus Co Debt-to-Equity?

Bio Plus Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩3,040 Mil. Bio Plus Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩1,972 Mil. Bio Plus Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩126,057 Mil. Bio Plus Co's debt to equity for the quarter that ended in Mar. 2024 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bio Plus Co's Debt-to-Equity or its related term are showing as below:

XKRX:099430' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.14
Current: 0.04

During the past 6 years, the highest Debt-to-Equity Ratio of Bio Plus Co was 0.14. The lowest was 0.00. And the median was 0.01.

XKRX:099430's Debt-to-Equity is ranked better than
83.67% of 698 companies
in the Medical Devices & Instruments industry
Industry Median: 0.215 vs XKRX:099430: 0.04

Bio Plus Co Debt-to-Equity Historical Data

The historical data trend for Bio Plus Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio Plus Co Debt-to-Equity Chart

Bio Plus Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.14

0.03

0.01

Bio Plus Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.01	0.01	0.02	0.04

Competitive Comparison of Bio Plus Co's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Bio Plus Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio Plus Co's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio Plus Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bio Plus Co's Debt-to-Equity falls into.

Bio Plus Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bio Plus Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(564.275	+	282.265)	/	113265.377
	=	0.01

Bio Plus Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3039.643	+	1971.849)	/	126056.794
	=	0.04

Bio Plus Co (XKRX:099430) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bio Plus Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bio Plus Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio Plus Co (XKRX:099430) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio Plus Co Ltd (XKRX:099430) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sagimakgol-ro 45th Street 14, Seongnam Woolim Lions Valley 2cha A-dong 180, Jungwon-gu, Gyeonggi-do, Seongnam-si, KOR

Website

https://www.ubioplus.com

Bio Plus Co Ltd is engaged in the development of innovative biomedical and medical devices products through research on bio-material applications platform technology.

Bio Plus Co (XKRX:099430) Headlines

No Headlines